Experts in dermatology discuss the occurrence of head and neck dermatitis and the difficulties in treatment.

Experts in dermatology share their counseling approach for patients taking dupilumab for atopic dermatitis.

Experts in dermatology discuss administering systemic treatments for atopic dermatitis in the climate of the COVID-19 pandemic

Emma Guttman, MD, PhD, reviews the use of systemic therapies in atopic dermatitis, including the latest evidence for the monoclonal antibody dupilumab.

Experts in dermatology review the use of skincare treatments, emollients, and topical corticosteroids in atopic dermatitis.

Experts in dermatology discuss the presentation of atopic dermatitis in pediatrics, adolescents, and adults, and the initial diagnosis.

Emma Guttman, MD, PhD, reviews the complex pathophysiology of atopic dermatitis and the differences between adults and children.

Linda Stein Gold, MD, discusses the impact atopic dermatitis has on the quality of life of pediatric and adult patients.

Emma Guttman, MD, PhD, reviews the prevalence of atopic dermatitis, the percentage of patients who outgrow their eczema, and risk factors.

Peter A. Lio, MD, gives a brief overview of atopic dermatitis and eczema, describing the differences between them and common misconceptions

Dr. Stephen Perkins explains the incidence and treatment of dry eye syndrome and chemosis in patients post-blepharoplasty.

Takeaways from a panel discussion on newer biologic therapies to treat plaque psoriasis, and parting advice to other professionals who work in dermatology regarding best practices when using these drugs in their clinics.

An overview of the most anticipated developments to come in plaque psoriasis treatment.

During a brief discussion on current treatment challenges in plaque psoriasis, key opinion leaders in dermatology highlight patient access and affordability of newer biologic therapies as the biggest hurdles faced by clinicians.

Recommendations for treating plaque psoriasis with newer biologic therapies and factors that warrant a switch in therapy, either using another biologic of the same class or moving to a different class.

Variables that dermatologists should consider when selecting an appropriate biologic therapy to treat a patient with plaque psoriasis, and the importance of shared decision-making.

Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center, highlights a newer class of biologics used to treat plaque psoriasis, IL-23 inhibitors, and explains how they differ from other classes of therapy.

Dermatology experts comment on the safety profiles of biologic therapies used to treat plaque psoriasis, highlight specific contraindications to be mindful of when prescribing these drugs, and provide suggestions to help mitigate the risk of adverse events.

A historical overview regarding the advances in biologic therapies to treat plaque psoriasis and real-world experience using newer classes of biologics in clinical practice.

An overview of current treatments used as initial therapy to treat plaque psoriasis and factors that affect treatment selection.